DOCSLIB.ORG

Architectures of US FDA Approved Pharmaceuticals Containing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Architectures of US FDA Approved Pharmaceuticals Containing Perspective Cite This: J. Med. Chem. 2018, 61, 10996−11020 pubs.acs.org/jmc From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles Michael D. Delost, David T. Smith, Benton J. Anderson, and Jon T. Njardarson* Department of Chemistry and Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States ABSTRACT: Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five. The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen- containing heterocycles. For each section, all oxygen hetero- cycle-containing drugs are presented along with a brief discussion about structural and drug application patterns. ■ INTRODUCTION Inspired by how much was learned by assembling and analyzing the 640 small molecule drugs containing nitrogen heterocycles1 as well as other educational endeavors,2 a similar study for oxygen heterocycles has now been completed. Analysis of our drug database (through 2017) unearthed a total of 311 unique oxygen heterocycle-containing pharmaceuticals, which is a significant representation (about 27% of unique approved small molecules and 15% of all approved drugs). In comparison, our group’s 2016 top 200 pharmaceutical prescription and retail sales posters reveal 17% and 16% representation of oxygen- heterocycle containing pharmaceuticals, respectively.3 Many of Downloaded via UNIV OF ARIZONA on August 6, 2021 at 17:18:02 (UTC). these drugs contain more than one oxygen heterocycle with a total of 389 oxygen heterocycles being part of these 311 drugs. Figure 1. Distribution of oxygen heterocycles according to ring size and For example, recently approved eteplirsen and mipomersen aromaticity. contain 30 and 20 oxygen heterocycles, respectively. In the See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. context of the evolutionarily selected structures carbohydrates ff fi and nucleosides, it is unsurprising that pyranoses and furanoses representation, respectively. Rounding o the top ve are are the top two most frequently employed oxygen heterocycles. macrocycles (10%) followed by three-membered (3%), seven- In this Perspective, all 311 U.S. FDA approved drugs containing membered (2%), and four-membered (1%) rings. oxygen heterocycles are presented, analyzed, and discussed in A closer look at the 311 unique oxygen heterocycle containing sections organized according to ring size or unique common U.S. FDA approved drugs reveals the majority (71%) are structural features. substituted with only one oxygen heterocycle (Figure 2), with The breakdown of the 389 oxygen heterocycles that are 13% and 6% consisting of two and three oxygen heterocycles, components of the 311 identified oxygen heterocyclic drugs is respectively. A decent number (3%) of these drugs are decorated presented according to ring size and presence or absence of with greater than eight oxygen heterocycles. Although the aromaticity in Figure 1. The majority (89%) of the oxygen atomic composition of the rings of these oxygen heterocycles fi primarily comprises one oxygen atom and carbon atoms (64%) heterocycles are nonaromatic; 95% of aromatic are ve- fi membered rings. These numbers are significantly higher than as one would nd in pyranoses, furanoses, etc., a large number for their nitrogen heterocyclic counterparts where 70% are (26%) also contain nitrogen, sulfur, boron, and even metal nonaromatic and 60% of the aromatic heterocycles are five- membered rings. With respect to ring size, five- and six- Received: June 2, 2018 membered rings reign supreme (84% total) with 46% and 38% Published: July 19, 2018 © 2018 American Chemical Society 10996 DOI: 10.1021/acs.jmedchem.8b00876 J. Med. Chem. 2018, 61, 10996−11020 Journal of Medicinal Chemistry Perspective Figure 2. Frequency and structural content of oxygen heterocycles. Figure 3. Most frequent oxygen heterocycles in U.S. FDA approved drugs. atoms, and 10% contain a second oxygen atom. The most drugs revealed that pyranoses are number 1 with 62 appearances common of these are rings composed of one oxygen and one (16%) followed by furanoses in a distant second place (9%). nitrogen atom, which are represented by members such as Macrolactones, morpholines, and dioxolanes account for the oxazoles and morpholines and their isomeric variants. Finally, remaining top five. These data for oxygen heterocycles are far most (75%) of these oxygen heterocycles are chiral. more top heavy in favor of one heterocycle (pyranose) when Our analysis led us to identify the top 27 most frequently compared with nitrogen heterocycles, with a 45% decrease occurring oxygen heterocycles in the FDA pharmaceutical between #1 (pyranose) and #2 (furanose) compared to 14% library (Figure 3). Analysis of the 389 oxygen heterocycles drop between (#1) piperidine and (#2) pyridine. In assembling contained within the 311 unique oxygen heterocycle-containing this top 27 list and deciding how to best convey the diversity of 10997 DOI: 10.1021/acs.jmedchem.8b00876 J. Med. Chem. 2018, 61, 10996−11020 Journal of Medicinal Chemistry Perspective Figure 4. Pharmaceuticals containing oxiranes. oxygen heterocycles presented in later sections, similar ring structures, drugs that contain more than one oxygen heterocycle types are organized according to their degree and location of appear in more than one section. For each section, the oxygen unsaturation as well as exact location of heteroatoms within a heterocycle of focus is highlighted in blue and drug structures are given ring and fusion with other rings. For example, pyranoses organized based on common disease indications. For drug are not the only six-membered rings containing a single oxygen families with high structural similarity, alphabetized colored atom in the top 27. Also belonging to this broad category would circles are employed to signify structural deviations from the be tetrahydropyrans, chromenes, chromanes, δ-lactones, and common core. dihydropyrans. Similarly, isoxazole and oxazole were categorized separately. Macrolactones (#3) make it into the top 10, which is ■ THREE-MEMBERED OXYGEN HETEROCYCLES in stark contrast to nitrogen heterocycles, for which no Oxiranes appear in 13 U.S. FDA approved drugs (Figure 4). macrocycles make it into the top 27. This is perhaps not With respect to oxirane substitution arrangements, only di- entirely surprising as macrocyclic drugs are commonly natural (69%) and trisubstituted oxiranes are represented. Three of the products or derivatives that usually contain 14- to 20-membered trisubstituted rings are part of fused natural product-type ring lactones. Dioxolanes, which chemists typically associate with # systems (eplerenone, trilostane, and picrotoxin), while one carbonyl protecting groups, are quite a surprise at 5 being part (ixabepilone) is nonfused. The disubstituted oxiranes can be of 24 approved drugs. Oxiranes appear highly on this list; this is further broken down into three categories: 1,1-disubstituted not the case for the three-membered nitrogen heterocycle (carfilzomib and troleandomycin), 1,2-trans-disubstituted (na- aziridine, which is only seen in a single U.S. FDA approved drug. tamycin and mupirocin), and 1,2-cis-disubstituted (scopol- Only 5 (19%) of the top 27 oxygen heterocycles are aromatic, amine, methyl scopolamine, tiotropium, cerulenin, and # with isoxazole ( 6) being the most commonly occurring. Two fosfomycin). These oxirane-containing drugs are structurally − (1,3-oxathiolane and boron oxygen heterocycles) of these top diverse with origins in natural products. Troleandomycin, structures contain atoms other than carbon, oxygen, or nitrogen natamycin, mupirocin, scopolamine, and picrotoxin are natural as part of their rings. Four fused ring types (morphine, products, while eplerenone, trilostane, tiotropium, and methyl chromene, benzofuran, and chromane) are represented, which scopolamine are natural products derived from steroids and is far fewer than for nitrogen heterocycles where 11 fused rings tropanes, respectively. Scopolamine, methyl scopolamine, and are highly ranked. Oxadiazoles are the only oxygen heterocycle tiotropium are anticholinergic drugs used to treat a variety of in the top 27 with two additional heteroatoms as part of the core conditions such as nausea, peptic ulcers, irritable bowel ring. Furthermore, 13 (48%) of the top 27 oxygen heterocycles syndrome, and chronic obstructive pulmonary disease are five-membered; 8 (30%) are six-membered. (COPD).4,5 These drugs are easily recognizable by their tropane In the sections that follow, all of the 311 unique oxygen ring. Fosfomycin, isolated from Streptomyces fradiae, is a broad- heterocycle-containing drugs are presented according to their spectrum antibiotic effective against both Gram-negative and ring size, from small to large starting with oxiranes and Gram-positive bacteria. Intriguingly, fosfomycin, with its small continuing all the way to macrocyclic structures, with the final size and phosphonic acid substitution at a reactive oxirane
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024
    IARC Monographs on the Identification of Carcinogenic Hazards to Humans Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 CONTENTS Introduction ................................................................................................................................... 1 Acetaldehyde (CAS No. 75-07-0) ................................................................................................. 3 Acrolein (CAS No. 107-02-8) ....................................................................................................... 4 Acrylamide (CAS No. 79-06-1) .................................................................................................... 5 Acrylonitrile (CAS No. 107-13-1) ................................................................................................ 6 Aflatoxins (CAS No. 1402-68-2) .................................................................................................. 8 Air pollutants and underlying mechanisms for breast cancer ....................................................... 9 Airborne gram-negative bacterial endotoxins ............................................................................. 10 Alachlor (chloroacetanilide herbicide) (CAS No. 15972-60-8) .................................................. 10 Aluminium (CAS No. 7429-90-5) .............................................................................................. 11
    [Show full text]
  • Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies
    Review Biomol Ther 19(4), 398-410 (2011) Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies Im-Soon Lee* Department of Biological Sciences and Center for Biotechnology Research in UBITA (CBRU), Konkuk University, Seoul 143-701, Republic of Korea Abstract Over the past few decades, our understanding of the epidemiology and immunopathogenesis of Hodgkin lymphoma (HL) has made enormous advances. Consequently, the treatment of HL has changed signifi cantly, rendering this disease of the most cur- able human cancers. To date, about 80% of patients achieve long-term disease-free survival. However, therapeutic challenges still remain, particularly regarding the salvage strategies for relapsed and refractory disease, which need further identifi cation of better prognostic markers and novel therapeutic schemes. Although the precise molecular mechanism by which Epstein-Barr virus (EBV) contributes to the generation of malignant cells present in HL still remains unknown, current increasing data on the role of EBV in the pathobiology of HL have encouraged people to start developing novel and specifi c therapeutic strategies for EBV- associated HL. This review will provide an overview of therapeutic approaches for acute EBV infection and the classical form of HL (cHL), especially focusing on EBV-associated HL cases. Key Words: Classical Hodgkin lymphoma, EBV, Hodgkin and Reed-Sternberg cells INTRODUCTION and Cole, 1980), and EBV DNA/RNA can be detected in HL tissues (Brink et al., 1997), suggesting that as a primary event Lymphoma is a type of cancer involving cells of the im- in the development of this disease, EBV infection may play a mune system, and has two major categories: Hodgkin lym- very crucial role in the pathogenesis of HL.
    [Show full text]
  • Cell Line Descriptions Geneblazer® M1-NFAT
    Version No.: GeneBLAzer ® Validation Packet Page 1 of 5 01Sep08 Optimization of the GeneBLazer ® M1-NFAT-bla Jurkat Cell Line GeneBLAzer ® M1 NFAT-bla Jurkat Cells Catalog Numbers – K1710 Cell Line Descriptions GeneBLAzer ® M1-NFAT-bla Jurkat cells contain the human Acetylcholine (muscarinic) subtype 1 receptor (M1), (Accession # NM_000738 ) stably integrated into the CellSensor ® NFAT-bla Jurkat cell line. CellSensor ® NFAT-bla Jurkat cells (Cat. no. K1671) contain a beta-lactamase (bla ) reporter gene under control of the Nuclear Factor of Activated T-cells (NFAT) response element. M1-NFAT-bla Jurkat cells are functionally validated for Z’-factor and EC 50 concentrations of carbachol (Figure 1). In addition, GeneBLAzer ® M1-NFAT-bla CHO-K1 cells have been tested for assay performance under variable conditions. Target Description Muscarinic acetylcholine receptors are members of the G protein-coupled receptor (GPCR) superfamily. Muscarinic receptors are widely distributed and mediate the actions of acetylcholine in both the CNS and peripheral tissues. Five muscarinic receptor subtypes have been identified and are referred to as M 1-M5 (1-5). The five genes that encode the muscarinic receptors all belong to the rhodopsin-line family (Family A) and share strong sequence homology but have unique regions located at the amino terminus (extracellular) and in the third intracellular loop. The M 1, M3, and M 5 receptor subtypes couple through the G q/11 class of G-proteins and activate the phopholipase C pathway. Activation of this pathway in turn leads to increases in free intracellular calcium levels as inositol triphosphate mediates release of calcium from the endoplasmic reticulum.
    [Show full text]
  • Crofelemer Oral Delayed Release Tablet
    Contains Nonbinding Recommendations Draft – Not for Implementation Draft Guidance on Crofelemer This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Crofelemer Dosage Form; Route: Tablet, delayed release; oral Strength: 125 mg Recommendations for the Assessment of Identity and Quality of Botanical Raw Material (BRM): Crofelemer is a botanical drug derived from BRM, the crude red latex of Croton lechleri Müll. Arg. [Fam. Euphorbiacae], which is also called dragon’s blood (sangre de drago). Generic drug applicants should use the same plant species and perform BRM assessment: 1. Crofelemer BRM should be collected from the crude red latex of Croton lechleri. The plant species should be correctly identified and authenticated based on techniques such as macroscopic/microscopic and/or analysis of genetic material. 2. Crude red latex as BRM should be collected from the mature tree with defined eco- geographic regions (EGRs). Implementing and enforcing established good agricultural and collection practice (GACP) procedures will minimize variations in BRM and ensure batch- to-batch consistency of crofelemer. 3. BRMs should be analyzed for their crofelemer content, total phenolics and taspine content, as well as heavy metals and pesticides. Recommendations for Demonstrating API Sameness: API sameness can be established by showing equivalence between Test API and API from the reference listed drug (RLD) product with the three criteria described in detail below.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Management of Adult Clostridium Difficile Digestive Contaminations: a Literature Review
    European Journal of Clinical Microbiology & Infectious Diseases (2019) 38:209–231 https://doi.org/10.1007/s10096-018-3419-z REVIEW Management of adult Clostridium difficile digestive contaminations: a literature review Fanny Mathias1 & Christophe Curti1,2 & Marc Montana1,3 & Charléric Bornet4 & Patrice Vanelle 1,2 Received: 5 October 2018 /Accepted: 30 October 2018 /Published online: 29 November 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Clostridium difficile infections (CDI) dramatically increased during the last decade and cause a major public health problem. Current treatments are limited by the high disease recurrence rate, severity of clinical forms, disruption of the gut microbiota, and colonization by vancomycin-resistant enterococci (VRE). In this review, we resumed current treatment options from official recommendation to promising alternatives available in the management of adult CDI, with regard to severity and recurring or non-recurring character of the infection. Vancomycin remains the first-line antibiotic in the management of mild to severe CDI. The use of metronidazole is discussed following the latest US recommendations that replaced it by fidaxomicin as first-line treatment of an initial episode of non-severe CDI. Fidaxomicin, the most recent antibiotic approved for CDI in adults, has several advantages compared to vancomycin and metronidazole, but its efficacy seems limited in cases of multiple recurrences. Innovative therapies such as fecal microbiota transplantation (FMT) and antitoxin antibodies were developed to limit the occurrence of recurrence of CDI. Research is therefore very active, and new antibiotics are being studied as surotomycin, cadazolid, and rinidazole. Keywords Clostridiumdifficile .Fidaxomicin .Fecalmicrobiotatransplantation .Antitoxinantibodies .Surotomycin .Cadazolid Introduction (Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110449 A1 Lorber Et Al
    US 200601 10449A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110449 A1 LOrber et al. (43) Pub. Date: May 25, 2006 (54) PHARMACEUTICAL COMPOSITION Publication Classification (76) Inventors: Richard R. Lorber, Scotch Plains, NJ (US); Heribert W. Staudinger, Union, (51) Int. Cl. NJ (US); Robert E. Ward, Summit, NJ A6II 3/473 (2006.01) (US) A6II 3L/24 (2006.01) Correspondence Address: A6IR 9/20 (2006.01) SCHERING-PLOUGH CORPORATION (52) U.S. Cl. ........................... 424/464; 514/290: 514/540 PATENT DEPARTMENT (K-6-1, 1990) 2000 GALLOPNG HILL ROAD KENILWORTH, NJ 07033-0530 (US) (57) ABSTRACT (21) Appl. No.: 11/257,348 (22) Filed: Oct. 24, 2005 The present invention relates to formulations useful for Related U.S. Application Data treating respiratory disorders associated with the production of mucus glycoprotein, skin disorders, and allergic conjunc (60) Provisional application No. 60/622,507, filed on Oct. tivitis while substantially reducing adverse effects associ 27, 2004. Provisional application No. 60/621,783, ated with the administration of non-selective anti-cholin filed on Oct. 25, 2004. ergic agents and methods of use thereof. US 2006/01 10449 A1 May 25, 2006 PHARMACEUTICAL COMPOSITION example, Weinstein and Weinstein (U.S. Pat. No. 6,086,914) describe methods of treating allergic rhinitis using an anti CROSS REFERENCE TO RELATED cholinergic agent with a limited capacity to pass across lipid APPLICATION membranes, such as the blood-brain barrier, in combination with an antihistamine that is limited in both sedating and 0001. This application claims benefit of priority to U.S.
    [Show full text]
  • Comparison of the Anti-Inflammatory Effects of Cilomilast, Budesonide
    Ratcliffe and Dougall BMC Pharmacology and Toxicology 2012, 13:15 http://www.biomedcentral.com/2050-6511/13/15 RESEARCH ARTICLE Open Access Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages Marianne Jennifer Ratcliffe1* and Iain Gordon Dougall2 Abstract Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by a largely irreversible airflow obstruction and a persistent, excessive inflammatory response. Alveolar macrophages (AMs) are increased in the lungs of COPD patients, and act as orchestrators of the inflammatory response, releasing a range of mediators to coordinate recruitment and activation of leukocytes. Attempts to treat the inflammatory component of COPD with anti-inflammatory drugs such as steroids has met with limited success. In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNFα) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. All studies were carried out with appropriate ethical approval and written, informed consent was obtained from each subject. Cilomilast had little effect on cytokine release from AMs. There was considerable variability in the responsiveness of AMs to Budesonide, with a subset of AMs responding poorly to Budesonide. BIRB-796 inhibited TNFα release from all AM donors, including those that responded poorly to steroids. Treatment with BIRB-796 and Budesonide together gave an additive decrease in TNFa release. These results suggest that a p38 inhibitor may provide advantages over existing anti-inflammatory treatments for COPD, either as an add-on to existing therapy, or to treat patients who respond poorly to steroids.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Perspectiva New Perspectives on the Treatment Of
    New Perspectives on the Treatment of Differentiated Thyroid Cancer perspectiva ABSTRACT Even though differentiated thyroid carcinoma is a slow growing and usu- ally curable disease, recurrence occurs in 20–40% and cellular dedifferen- SABRINA MENDES COELHO tiation in up to 5% of cases. Conventional chemotherapy and radiotherapy DENISE PIRES DE CARVALHO have just a modest effect on advanced thyroid cancer. Therefore, dediffer- entiated thyroid cancer represents a therapeutic dilemma and a critical MÁRIO VAISMAN area of research. Targeted therapy, a new generation of anticancer treat- ment, is planned to interfere with a specific molecular target, typically a protein that is believed to have a critical role in tumor growth or progres- sion. Since many of the tumor-initiation events have already been identi- Serviço de Endocrinologia do fied in thyroid carcinogenesis, targeted therapy is a promising therapeutic Hospital Universitário Clementino tool for advanced thyroid cancer. Several new drugs are currently being Fraga Filho (SMC & MV) e Labo- tested in in vitro and in vivo studies and some of them are already being ratório de Fisiologia Endócrina used in clinical trials, like small molecule tyrosine kinase inhibitors. In this da Universidade Federal do Rio review, we discuss the bases of targeted therapies, the principal drugs de Janeiro (DPC), Rio de already tested and also options of redifferentiation therapy for thyroid car- Janeiro, RJ. cinoma. (Arq Bras Endocrinol Metab 2007;51/4:612-624) Keywords: Thyroid cancer; Redifferentiation therapy; Targeted therapy; Tyrosine kinase inhibitors RESUMO Novas Perspectivas no Tratamento do Carcinoma Diferenciado da Tireóide. Apesar de o carcinoma diferenciado da tireóide ser considerado uma doença de curso indolente e geralmente curável, recorrência tumoral ocorre em aproximadamente 20 a 40% e desdiferenciação celular, em até 5% dos casos.
    [Show full text]
  • Phototoxicity of 7-Oxycoumarins with Keratinocytes in Culture T ⁎ Christophe Guillona, , Yi-Hua Janb, Diane E
    Bioorganic Chemistry 89 (2019) 103014 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg Phototoxicity of 7-oxycoumarins with keratinocytes in culture T ⁎ Christophe Guillona, , Yi-Hua Janb, Diane E. Heckc, Thomas M. Marianob, Robert D. Rappa, Michele Jettera, Keith Kardosa, Marilyn Whittemored, Eric Akyeaa, Ivan Jabine, Jeffrey D. Laskinb, Ned D. Heindela a Department of Chemistry, Lehigh University, Bethlehem, PA 18015, USA b Department of Environmental and Occupational Health, Rutgers University School of Public Health, Piscataway, NJ 08854, USA c Department of Environmental Science, New York Medical College, Valhalla, NY 10595, USA d Buckman Laboratories, 1256 N. McLean Blvd, Memphis, TN 38108, USA e Laboratoire de Chimie Organique, Université Libre de Bruxelles, B-1050 Brussels, Belgium ARTICLE INFO ABSTRACT Keywords: Seventy-one 7-oxycoumarins, 66 synthesized and 5 commercially sourced, were tested for their ability to inhibit 7-hydroxycoumarins growth in murine PAM212 keratinocytes. Forty-nine compounds from the library demonstrated light-induced 7-oxycoumarins lethality. None was toxic in the absence of UVA light. Structure-activity correlations indicate that the ability of Furocoumarins the compounds to inhibit cell growth was dependent not only on their physiochemical characteristics, but also Psoralens on their ability to absorb UVA light. Relative lipophilicity was an important factor as was electron density in the Methoxsalen pyrone ring. Coumarins with electron withdrawing moieties – cyano and fluoro at C – were considerably less 8-MOP 3 Phototoxicity active while those with bromines or iodine at that location displayed enhanced activity. Coumarins that were PAM212 keratinocytes found to inhibit keratinocyte growth were also tested for photo-induced DNA plasmid nicking.
    [Show full text]